27 results about "Increased risk" patented technology

The present disclosure describes methods and systems for predicting if a subject has an increased risk of having or developing one or more clinical outcomes, including prior to the detection of symptoms thereof and / or prior to onset of any detectable symptoms thereof. The present disclosure also describes a method of generating a model for predicting one or more clinical outcomes.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

The invention provides methods for prognosing an increased risk of early onset preeclampsia (EOPE) in a pregnant subject before the disease onset. The methods comprises quantifying small extracellular vesicles that express pairs of biomarkers selected from CD10, CD63 and placental alkaline phosphatase (PLAP) in a sample obtained from the subject.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor:(Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.

This utility model belongs to the field of yak disease prevention technology, specifically a yak disease prevention passageway. Addressing the problems of existing yak disease prevention passageways causing congestion and slow isolation during the transfer of suspected sick yaks, as well as limited spray range, incomplete disinfection, and increased risk of disease transmission, this invention proposes the following solution: It includes a main containment area and at least two sub-containment areas. A trapezoidal inspection passageway, wider at the top and narrower at the bottom, is provided between the main and sub-containment areas. Both ends of the inspection passageway connect to a self-propelled passageway. In this utility model, a reasonable passageway is constructed using trapezoidal frames to ensure orderly passage of yaks. Simultaneously, the drive component, in conjunction with the guardrail, allows for the rapid and safe transfer of sick yaks to the isolation area. A cylinder-driven fixing frame stabilizes and restrains the yaks, while the spray nozzles of disinfection pipes I and II achieve comprehensive disinfection. The coordinated operation of all components ensures efficient and continuous disease prevention, weighing, and isolation, reducing manpower and lowering the risk of disease transmission.

The invention provides methods of screening a subject for a proliferative disease risk factor which comprises detecting the presence or absence of target cells. The presence of target cells in the subject indicates the subject is at increased risk of developing a proliferative disease or recurrence of a previously treated proliferative disease and defines a new patient subgroup susceptible for treatment with selected anti-proliferative compounds. Methods of screening compounds for the treatment of proliferative diseases based on the presence of target cells and the expression of certain biomarkers by said target cells are also disclosed, along with appropriate compounds and their use in methods of treating such diseases.

The invention relates to in situ methods for detecting the presence of misfolded proteins in samples (e.g. tissue samples). The invention also relates to the use of said methods in the detection of a proteinopathy or an increased risk thereof in a subject and to methods of determining the efficacy of therapeutic interventions.

In certain embodiments, the present invention provides a panel of probes to detect biomarkers associated with ovarian cancer, wherein the probes hybridize to the biomarkers. Certain embodiments provide kits that comprise a panel of probes to detect biomarkers associated with ovarian cancer. In certain embodiments, the present invention provides a method of detecting the presence of biomarkers associated with an increased risk of ovarian cancer in a human subject. In certain embodiments, the present invention provides a method of treating a human subject for ovarian cancer.

The invention provides a compound characterized by formula (1): X1-Thr-Thr-Ala-Arg-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further provides an in vitro method for detecting protease activity in a subject's body fluid, comprising contacting the body fluid with the compound of the invention and detecting a signal, wherein the body fluid may comprise a hydrolytic enzyme derived from pancreatic cancer cells. Furthermore, the invention provides a kit comprising the compound of the invention and a measurement buffer. In addition, the invention provides the use of the compound, the in vitro method or the kit of the invention for the detection of pancreatic cancer, or for monitoring a subject that is suspected of having pancreatic cancer, has an increased risk of developing pancreatic cancer, or has had pancreatic cancer. The invention also provides the use of the compound of the invention in a method of treating pancreatic cancer, the method comprising carrying out the in vitro method for detecting protease activity in a subject's body fluid, and treating pancreatic cancer in a subject for which protease activity, has been detected.

The present invention relates to the diagnosis of sepsis and / or septic shock and monitoring the extent thereof; the early assessment of the risk of developing sepsis and / or septic shock; the prediction or determination or monitoring of the need for a therapy or intervention in a subject. The present invention relates to a method which comprises determining the level of a biomarker selected from the group consisting of ADM-Gly, PAMP, MR-proADM and CT-proADM or a fragment of at least five amino acids thereof, or the total ADM, or the ratio of the level of said biomarker to the level of ADM-Nffz, in a sample of a subject, and wherein the level of said biomarker or said ratio is indicative of sepsis and / or septic shock or the extent of sepsis and / or septic shock, or is predictive of an increased risk of developing sepsis and / or septic shock, or is indicative of the need for a therapy or intervention in said subject for sepsis and / or septic shock.

The invention discloses a dangerous stratification model for hypertrophic cardiomyopathy and a preparation method and application thereof, and belongs to the technical field of biological medicine. The invention provides application of a reagent for detecting the expression level of PDCD5 protein. Researches find that expression increase of the serum PDCD5 protein is not only a risk factor of bad outcome of HCM patients, but also is independent of other clinical factors, and a survival curve of risk stratification according to the serum PDCD5 protein also has a good discrimination degree. The PDCD5 protein improves a risk stratification model of HCM established based on clinical factors. The non-synonymous variation of the VWCE, SPAG5, PDGFRB and PITX3 genes is independently related to the increase of the adverse outcome risk of HCM patients; on the basis of a score 2 established based on serum PDCD5 protein and clinical factors, the non-synonymous variation of the genes is combined, and the established multi-dimensional risk stratification model has good prediction efficiency on the adverse outcome of the HCM patient.

It is provided a sensor for measuring a biomarker or metabolite level such as glucose level in a fluid sample such as saliva comprising a sensing element comprising a redox reporter attached to at least one aptamer that binds to the biomarker or metabolite, and a solid surface where the sensing element is attached thereto, wherein upon binding of the biomarker or metabolite onto to the aptamer, the redox reporter undergoes a binding-induced change in electron transfer. Measuring the biomarker or metabolite level in the saliva of a patient will allow health monitoring in the patient such as increased risk of gum disease or diabetes in the patient.

The present disclosure provides methods of treating subjects having psoriasis, and methods of identifying subjects having an increased risk of developing psoriasis.

A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Methods for identifying biomarkers indicative of an increased risk for developing hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunting (TIPS) are provided. Methods include determining whether the subject has a decreased level of metabolites following transjugular intrahepatic portosystemic shunting (TIPS), and / or determining a level of intrahepatic shunting in the subject. Methods for preventing and treating a subject having or at risk of having HE identified by the methods disclosed.

This disclosure relates to miRNA-related reagents and methods for identifying health risks during pregnancy. In preferred embodiments, the miRNAs are selected from those disclosed herein that in a pregnant human being indicate an increased risk of developing a placental bed disorder as compared to the control sample. In some preferred embodiments, such miRNAs are selected from the group consisting of hsa-miR-150-5p, hsa-let-7g-5p, hsa-miR-16-5p, hsa-miR-29a-3p, hsa-let-7f-5p, hsa-miR-15b-5p, hsa-let-7i-5p, hsa-miR-26b-5p, hsa-miR-223-3p, hsa-miR-21-5p, hsa-miR-23a-3p, hsa-miR-142-3p, hsa-miR-19b-3p, hsa-let-7a-5p, hsa-miR-22-3p, hsa-miR-29c-3p, hsa-miR-342-3p, hsa-miR-25-3p, hsa-miR-24-3p, and hsa-miR-17-5p.

A method for identifying whether a subject diagnosed with or suspected to have a liver disease (e.g., non-alcohol-related fatty liver disease, non-alcohol-related steatohepatitis, hepatitis, cirrhosis, or cancer), has or is at an increased risk of developing one or more second diseases or conditions. The method involves providing a cell-free deoxyribonucleic acid (cfDNA) sample derived from the subject, assaying the cfDNA sample or a derivative thereof to determine a methylation pattern or a methylation level of DNA molecules, processing the methylation pattern or the methylation level using a trained machine learning algorithm to generate an output indicative of whether the cfDNA sample is positive for the one or more second diseases or conditions, and based at least in part on the output, generating an electronic report that is indicative of the subject having or being at the increased risk of developing the one or more second diseases or conditions.

This invention relates to the fields of environmental medicine and molecular biology, and discloses a method and application for assessing the increased risk of type 2 diabetes due to acrylamide exposure. The method involves obtaining in vitro biological samples, detecting the expression level of miR-128-1, and comparing it with a reference value. A level higher than the reference value suggests a tendency for increased type 2 diabetes due to acrylamide exposure. This method can also detect acrylamide exposure biomarkers and oxidative stress or NRF2 pathway-related factors for non-diagnostic risk assessment. The invention also provides the application of miR-128-1 inhibitors in the preparation of related drugs. This invention integrates the assessment strategy of exposure and effect biomarkers and provides a clear molecular intervention target, solving the problem of the lack of integrated assessment methods and intervention targets in existing technologies.

To provide an in vitro method for assessing the risk of developing sepsis, systemic inflammatory response syndrome (SIRS), septic shock, or multiple organ dysfunction syndrome (MODS) in a subject. Also provided are pharmaceutical compositions for the treatment of sepsis, SIRS, septic shock or MODS in a subject.SOLUTION: Determining or having determined the presence or absence of i) a PCSK9 variant nucleic acid sequence encoding a Pro-protein convertase subtilisin / kexin type 9 (Arg46Leu) PCSK9; and ii) a low-density-lipoprotein receptor (LDLR) variant nucleic acid sequence comprising a single nucleotide polymorphism rs6511720 in a biological sample obtained from the subject, wherein the subject is a PCSK9 reference and being a LDLR reference indicates that the subject has an increased risk of developing SIRS / MODS.SELECTED DRAWING: None

Methods of treating a patient suffering from an interleukin (IL) -33-mediated disorder and methods for determining whether a patient is at increased risk of suffering from an IL-33-mediated disorder or methods for determining whether a patient suffering from a disorder has an increased likelihood of responding to an anti-IL-33 therapy are provided.SOLUTION: A method for treating a patient suffering from asthma, the method comprising administering an IL-33 axis binding antagonist to the patient, wherein the patient's genotype has been determined to comprise at least one allele of a cluster 2 polymorphism defined elsewhere or an equivalent allele at a polymorphism in linkage disequilibrium therewith.SELECTED DRAWING: None

The present disclosure relates generally to methods of treating a subject having or at risk of developing macular degeneration by administering a complement factor D (CFD) inhibitor to the subject and to identifying subjects at increased risk of developing macular degeneration.

This disclosure relates to cardiac autoantibodies in type 1 diabetes (T1D) and in subjects treated with immune checkpoint inhibitors (ICI) such as cancer subjects, including autoantibodies to myosin heavy chain 6 (MYH6), myosin heavy chain 7 (MYH7), S1-fragment of myosin heavy chain 6, S2-fragment of myosin heavy chain 6, and cardiac troponin I (cTnI). Described herein are uses of these autoantibodies as markers for assessing a person's risk of developing cardiovascular disease.

A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM-1 antibody to a nanoparticle. The composition may be used as an imaging agent and / or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

Disclosed herein are methods, systems, and kits relating to identifying a subject as having or being at an increased risk of having a disease. The methods may include processing a biological sample obtained from an oral cavity of the subject at an oral point of care location. The methods may include generating a report identifying the subject as having or being at an increased risk of having the disease. The report may be generated remotely.

Compositions and methods for diagnosis and treatment of increased risk for mild traumatic brain injury are disclosed.

Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and / or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels. 20 24 20 20 18 28 M ar 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 0 1 8 2 8 M a r 2 0 2 4